Centogene (CNTG) Set to Announce Quarterly Earnings on Wednesday

Centogene (NASDAQ:CNTG) will be posting its quarterly earnings results before the market opens on Wednesday, June 16th. Analysts expect Centogene to post earnings of ($0.30) per share for the quarter.

Centogene (NASDAQ:CNTG) last announced its quarterly earnings results on Wednesday, April 14th. The company reported $0.18 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.08) by $0.26. Centogene had a negative net margin of 15.78% and a negative return on equity of 38.38%. The business had revenue of $83.79 million for the quarter. On average, analysts expect Centogene to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Shares of NASDAQ CNTG opened at $9.93 on Friday. Centogene has a fifty-two week low of $8.61 and a fifty-two week high of $27.10. The company has a market cap of $197.22 million, a PE ratio of -8.63 and a beta of -2.15. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.50 and a current ratio of 1.70. The company has a 50-day simple moving average of $10.57.

Several equities analysts recently weighed in on the stock. Zacks Investment Research raised shares of Centogene from a “hold” rating to a “buy” rating and set a $13.00 price target on the stock in a research report on Tuesday, April 20th. Robert W. Baird reissued a “buy” rating and set a $19.00 target price on shares of Centogene in a research report on Sunday, April 18th. Five analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and an average price target of $17.25.

Centogene Company Profile

Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. The company develops rare disease platform, a data repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs.

Featured Article: Back-End Load

Earnings History for Centogene (NASDAQ:CNTG)

Receive News & Ratings for Centogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centogene and related companies with MarketBeat.com's FREE daily email newsletter.